Progyny

PGNY

Market cap $1.94B

Overview Fund Activity

22.56 USD

+0.93

4.3%

At close Updated Sep 18, 1:44 PM EDT

1 day

4.3%

5 days

-2.25%

1 month

-5.13%

3 months

4.2%

6 months

6.36%

Year to date

27.24%

1 year

-7.69%

5 years

-14.38%

10 years

41.53%

About: Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.

Employees: 680

Healthcare Healthcare Plans

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

426% more call options, than puts

Call options by funds: $7.08M | Put options by funds: $1.35M

41% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 34

5.43% more ownership

Funds ownership: 90.37% [Q1] → 95.8% (+5.43%) [Q2]

4% more funds holding

Funds holding: 288 [Q1] → 300 (+12) [Q2]

5% more capital invested

Capital invested by funds: $1.72B [Q1] → $1.81B (+$83.2M) [Q2]

6% less repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 113

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$23

2% upside

Avg. target

$26

16% upside

High target

$28

24% upside

5 analyst ratings

2 positive

40%

3 neutral

60%

0 negative

0%

JP Morgan Anne Samuel	$25	Neutral Maintained	26 Aug 2025
Canaccord Genuity Richard Close	$23	Hold Maintained	20 Aug 2025
Cantor Fitzgerald Sarah James	$28	Overweight Maintained	8 Aug 2025
Truist Securities Jailendra Singh	$27	Hold Maintained	17 Jul 2025
Leerink Partners Michael Cherny	$28	Outperform Upgraded	8 Jul 2025

See Analyst Rankings

Financial journalist opinion

Progyny's Strong Fundamentals & Global Growth: Why I Choose To BUY

Progyny's fundamentals remain strong with solid revenue growth, impressive cash flow, and a debt-free balance sheet despite recent share price weakness. The company is expanding globally via Progyny Global, diversifying revenue streams and offsetting the loss of a major client, which demonstrates resilience. Valuation is at a premium, reflecting strong growth prospects, but investors should monitor client concentration and competitive risks.

Progyny's Strong Fundamentals & Global Growth: Why I Choose To BUY

Zacks Investment Research

Surging Earnings Estimates Signal Upside for Progyny (PGNY) Stock

Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Progyny (PGNY) Stock

Progyny, Inc. (PGNY) Q2 2025 Earnings Call Transcript

Progyny, Inc. (NASDAQ:PGNY ) Q2 2025 Earnings Conference Call August 7, 2025 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Mark S. Livingston - Chief Financial Officer Michael Sturmer - President Peter Anevski - CEO & Director Conference Call Participants Brian Gil Tanquilut - Jefferies LLC, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Larsen - BTIG, LLC, Research Division Jailendra P.

Progyny, Inc. (PGNY) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Progyny (PGNY) Tops Q2 Earnings and Revenue Estimates

Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.43 per share a year ago.

Progyny (PGNY) Tops Q2 Earnings and Revenue Estimates

Progyny, Inc. Announces Second Quarter 2025 Results

Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement

Progyny, Inc. Announces Second Quarter 2025 Results

Zacks Investment Research

Progyny (PGNY) Earnings Expected to Grow: Should You Buy?

Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Progyny (PGNY) Earnings Expected to Grow: Should You Buy?

New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage

Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings

New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage

Zacks Investment Research

Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?

Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?

Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA , maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights.

Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

Zacks Investment Research

Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?

Progyny (PGNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?

See News Rankings

Charts implemented using Lightweight Charts™